Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 17, 2018. The document serves as a transaction notification reporting insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The filing details acquisitions of company securities resulting from dividend reinvestment plans.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share transactions.
| Instrument | Transaction Price | Exchange | Transaction Date |
|---|---|---|---|
| Ordinary Shares (GBP) | £14.296 | London Stock Exchange (XLON) | April 12, 2018 |
| American Depositary Shares (USD) | $40.62 | New York Stock Exchange (XNYS) | April 12, 2018 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses routine acquisitions of shares by executives via the Deferred Annual Bonus Plan following the dividend payment on April 12, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of specific share purchase volumes and prices for compliance purposes.
Important Facts for Investors
- Transaction Nature: All reported transactions were acquisitions of Ordinary Shares or ADSs resulting from the reinvestment of dividends paid on April 12, 2018, under the Company's Deferred Annual Bonus Plan.
- Participants: Transactions involved senior executives including the CEO (Ms E Walmsley), CFO (Mr S Dingemans), and various Presidents and SVPs.
- Trading Volume: Individual transaction volumes ranged from approximately 100 to 1,986 shares/ADSs per executive.
- Market Data: The filing confirms the trading price of Ordinary Shares at £14.296 and ADSs at $40.62 on the transaction date.